02:53 AM EDT, 09/10/2026 (MT Newswires) -- Orexo's (ORX.ST) US subsidiary received an additional $3 million from the Biomedical Advanced Research and Development Authority for the OX390 project, the Swedish pharmaceutical company said Thursday. The additional funding will extend the initial development stage of OX390, an intranasal rescue medication to treat respiratory depression associated with adulterated opioid overdoses, from March 2027 through the end of 2027. It increases the overall potential value of the contract, initially awarded in September 2025, to $53.8 million from $50.9 million. Orexo said the funding will also support the potential submission to and approval by the US Food and Drug Administration.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.